Last reviewed · How we verify

placebo adalimumab, placebo MTX

Abbott · Phase 3 active Small molecule

placebo adalimumab, placebo MTX is a TNF-alpha inhibitor Small molecule drug developed by Abbott. It is currently in Phase 3 development for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis. Also known as: placebo.

Adalimumab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby reducing inflammation.

Adalimumab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby reducing inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.

At a glance

Generic nameplacebo adalimumab, placebo MTX
Also known asplacebo
SponsorAbbott
Drug classTNF-alpha inhibitor
TargetTNF-alpha
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

TNF-alpha is a cytokine that plays a key role in systemic inflammation, and its blockade has been shown to be effective in treating various autoimmune diseases. By binding to TNF-alpha, adalimumab prevents the activation of immune cells and the release of pro-inflammatory cytokines, leading to a reduction in inflammation and disease symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about placebo adalimumab, placebo MTX

What is placebo adalimumab, placebo MTX?

placebo adalimumab, placebo MTX is a TNF-alpha inhibitor drug developed by Abbott, indicated for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.

How does placebo adalimumab, placebo MTX work?

Adalimumab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby reducing inflammation.

What is placebo adalimumab, placebo MTX used for?

placebo adalimumab, placebo MTX is indicated for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Crohn's disease, Ulcerative colitis.

Who makes placebo adalimumab, placebo MTX?

placebo adalimumab, placebo MTX is developed by Abbott (see full Abbott pipeline at /company/abbott).

Is placebo adalimumab, placebo MTX also known as anything else?

placebo adalimumab, placebo MTX is also known as placebo.

What drug class is placebo adalimumab, placebo MTX in?

placebo adalimumab, placebo MTX belongs to the TNF-alpha inhibitor class. See all TNF-alpha inhibitor drugs at /class/tnf-alpha-inhibitor.

What development phase is placebo adalimumab, placebo MTX in?

placebo adalimumab, placebo MTX is in Phase 3.

What are the side effects of placebo adalimumab, placebo MTX?

Common side effects of placebo adalimumab, placebo MTX include Injection site reaction, Headache, Fatigue, Muscle pain, Nausea.

What does placebo adalimumab, placebo MTX target?

placebo adalimumab, placebo MTX targets TNF-alpha and is a TNF-alpha inhibitor.

Related